Nothing Special   »   [go: up one dir, main page]

MD20210033A2 - Compuşi, compoziţii şi metode pentru modularea activităţii CDK9 - Google Patents

Compuşi, compoziţii şi metode pentru modularea activităţii CDK9

Info

Publication number
MD20210033A2
MD20210033A2 MDA20210033A MD20210033A MD20210033A2 MD 20210033 A2 MD20210033 A2 MD 20210033A2 MD A20210033 A MDA20210033 A MD A20210033A MD 20210033 A MD20210033 A MD 20210033A MD 20210033 A2 MD20210033 A2 MD 20210033A2
Authority
MD
Moldova
Prior art keywords
compounds
methods
cdk9
compositions
modulating
Prior art date
Application number
MDA20210033A
Other languages
English (en)
Russian (ru)
Inventor
Петер МИКОЧИК
Джозеф ВАККА
Дэвид ФРИМАН
Эндрю Таскер
Original Assignee
Kronos Bio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kronos Bio, Inc. filed Critical Kronos Bio, Inc.
Publication of MD20210033A2 publication Critical patent/MD20210033A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Invenţia se referă la compuşi, care modulează activitatea kinazei dependente de ciclină 9 (CDK9), compoziţii farmaceutice, care conţin astfel de compuşi, şi metode de utilizare a compuşilor şi/sau compoziţiilor farmaceutice pentru tratamentul, ameliorarea şi/sau prevenirea bolilor, care apar în rezultatul activităţii CDK9, de exemplu, bolilor hiperproliferative, bolilor infecţioase, induse de virus, şi bolilor cardiovasculare.Inhibitorii ai CDK9 reprezintă derivaţi de pirazolo[1,5-a]pirimidine şi sărurile lor, corespunzători formulei (I): (I).
MDA20210033A 2018-10-30 2019-10-29 Compuşi, compoziţii şi metode pentru modularea activităţii CDK9 MD20210033A2 (ro)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862752635P 2018-10-30 2018-10-30
US201962884993P 2019-08-09 2019-08-09
US201962910058P 2019-10-03 2019-10-03
PCT/US2019/058482 WO2020092314A1 (en) 2018-10-30 2019-10-29 Compounds, compositions, and methods for modulating cdk9 activity

Publications (1)

Publication Number Publication Date
MD20210033A2 true MD20210033A2 (ro) 2021-10-31

Family

ID=70328627

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20210033A MD20210033A2 (ro) 2018-10-30 2019-10-29 Compuşi, compoziţii şi metode pentru modularea activităţii CDK9

Country Status (20)

Country Link
US (3) US11155560B2 (ro)
EP (1) EP3873911A4 (ro)
JP (1) JP7385658B2 (ro)
KR (1) KR20210068597A (ro)
CN (1) CN112996790B (ro)
AU (1) AU2019370200A1 (ro)
BR (1) BR112021008176A2 (ro)
CA (1) CA3118472A1 (ro)
CO (1) CO2021005502A2 (ro)
CR (1) CR20210202A (ro)
DO (1) DOP2021000066A (ro)
IL (1) IL282254A (ro)
MA (1) MA54092A (ro)
MD (1) MD20210033A2 (ro)
MX (1) MX2021004769A (ro)
PE (1) PE20212196A1 (ro)
PH (1) PH12021550857A1 (ro)
SG (1) SG11202104229WA (ro)
WO (1) WO2020092314A1 (ro)
ZA (1) ZA202102609B (ro)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD20210033A2 (ro) * 2018-10-30 2021-10-31 Kronos Bio, Inc. Compuşi, compoziţii şi metode pentru modularea activităţii CDK9
WO2021216828A1 (en) * 2020-04-24 2021-10-28 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
JP2023548335A (ja) * 2020-11-05 2023-11-16 クロノス バイオ インコーポレイテッド Ｃｄｋ９活性を調節するための化合物および方法
CN118678952A (zh) * 2021-11-24 2024-09-20 克洛诺斯生物股份有限公司 (1S,3S)-N1-(5-(戊-3-基)吡唑并[1,5-a]嘧啶-7-基)环戊烷-1,3-二胺的多晶型和盐形式
WO2024017365A1 (zh) * 2022-07-22 2024-01-25 上海海雁医药科技有限公司 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物的药学上可接受的盐和多晶型物及其应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
KR100315837B1 (ko) * 1994-06-21 2002-02-28 고리 히데아끼 피라졸로[1,5-a]피리미딘유도체
ATE375344T1 (de) 1996-07-24 2007-10-15 Bristol Myers Squibb Pharma Co Azolotriazine und pyrimidine
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
YU23602A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
EA200200422A1 (ru) 1999-09-30 2002-10-31 Ньюроджен Корпорейшн НЕКОТОРЫЕ АЛКИЛЕНДИАМИНОЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]-1,5-ПИРИМИДИНЫ И ПИРАЗОЛО[1,5-а]-1,3,5-ТРИАЗИНЫ
JP2002308879A (ja) 2001-04-13 2002-10-23 Nippon Soda Co Ltd ５−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤
CN100343255C (zh) 2002-04-23 2007-10-17 盐野义制药株式会社 吡唑并[1,5－a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂
AU2003228770A1 (en) 2002-05-10 2003-11-11 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
DE60319820T2 (de) 2002-06-04 2009-03-26 Schering Corp. Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
MY137843A (en) * 2002-09-04 2009-03-31 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
NZ539165A (en) * 2002-09-04 2008-03-28 Schering Corp Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
GB0305559D0 (en) 2003-03-11 2003-04-16 Teijin Ltd Compounds
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
JPWO2005035516A1 (ja) 2003-10-10 2006-12-21 小野薬品工業株式会社 新規縮合複素環化合物およびその用途
WO2005063756A1 (en) 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
US8018479B2 (en) 2008-08-27 2011-09-13 Lexmark International, Inc. Method and system for correcting the linearity error in electrophotographic devices
AU2005272298A1 (en) * 2004-08-13 2006-02-16 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivative
ATE433454T1 (de) 2004-12-21 2009-06-15 Schering Corp Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
US7645762B2 (en) 2005-10-06 2010-01-12 Schering Corporation Substituted pyrazolo[1,5-a] pyrimidines as protein kinase inhibitors
EP1942900B1 (en) 2005-10-06 2015-06-03 Merck Sharp & Dohme Corp. Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases
EP1945220A1 (en) 2005-10-21 2008-07-23 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
WO2007109571A2 (en) 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
JP2009538304A (ja) 2006-05-22 2009-11-05 シェーリング コーポレイション ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］ピリミジン
AU2008261027A1 (en) 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
EP2173346A2 (en) 2007-06-27 2010-04-14 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
US20110201599A1 (en) * 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators
WO2010074284A1 (ja) 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8575177B2 (en) 2009-12-04 2013-11-05 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
TWI476200B (zh) 2010-02-26 2015-03-11 Mitsubishi Tanabe Pharma Corp 吡唑並嘧啶化合物及其充作ｐｄｅ１０抑制劑之用途
JP5688404B2 (ja) 2010-03-05 2015-03-25 協和発酵キリン株式会社 ピラゾロピリミジン誘導体
EP3012258B1 (en) 2010-06-24 2018-09-19 Gilead Sciences, Inc. Pharmaceutical composition comprising a pyrazolo[1,5-a]pyrimidine derivative as an antiviral agent
CN105367577B (zh) 2010-07-13 2019-04-23 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2621926B1 (en) 2010-09-30 2017-08-30 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde10 inhibitors
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
JP6106694B2 (ja) 2012-01-10 2017-04-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔキナーゼ阻害剤としての置換ピラゾロピリミジン類
EP3536692B1 (en) 2012-02-17 2021-04-07 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
CA2889919C (en) 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
US10844436B2 (en) 2014-04-01 2020-11-24 Cornell University Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection
WO2015154022A1 (en) 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016142855A2 (en) 2015-03-09 2016-09-15 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
CA2978518C (en) * 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
US9828381B2 (en) 2015-04-20 2017-11-28 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
AU2016276963C1 (en) * 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
ES2767776T3 (es) 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
WO2017180499A2 (en) 2016-04-13 2017-10-19 President And Fellows Of Harvard College Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof
CN117946115A (zh) 2017-07-28 2024-04-30 武田药品工业株式会社 Tyk2抑制剂与其用途
US20190060296A1 (en) * 2017-07-28 2019-02-28 Massachusetts Institute Of Technology Discovery of small molecules that target the androgen receptor and uses
MD20210033A2 (ro) * 2018-10-30 2021-10-31 Kronos Bio, Inc. Compuşi, compoziţii şi metode pentru modularea activităţii CDK9

Also Published As

Publication number Publication date
JP7385658B2 (ja) 2023-11-22
PH12021550857A1 (en) 2021-12-06
US11155560B2 (en) 2021-10-26
CN112996790B (zh) 2023-11-03
WO2020092314A1 (en) 2020-05-07
DOP2021000066A (es) 2021-10-31
ZA202102609B (en) 2023-02-22
US20200131189A1 (en) 2020-04-30
US20220002305A1 (en) 2022-01-06
CR20210202A (es) 2022-02-08
JP2022505268A (ja) 2022-01-14
BR112021008176A2 (pt) 2021-08-03
CO2021005502A2 (es) 2021-09-20
CA3118472A1 (en) 2020-05-07
CN112996790A (zh) 2021-06-18
PE20212196A1 (es) 2021-11-16
IL282254A (en) 2021-05-31
MX2021004769A (es) 2021-08-24
US11845754B2 (en) 2023-12-19
US20240132506A1 (en) 2024-04-25
SG11202104229WA (en) 2021-05-28
MA54092A (fr) 2021-09-08
EP3873911A1 (en) 2021-09-08
KR20210068597A (ko) 2021-06-09
AU2019370200A1 (en) 2021-06-10
EP3873911A4 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
MD20210033A2 (ro) Compuşi, compoziţii şi metode pentru modularea activităţii CDK9
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
PH12019501941A1 (en) Jak inhibitors containing a 4-membered heterocyclic amide
CA2962914C (en) Compounds and compositions for modulating egfr mutant kinase activities
WO2017204445A3 (ko) Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201991884A3 (ru) Ингибиторы g12c kras
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
EA202091372A1 (ru) Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
WO2015200677A8 (en) Prmt5 inhibitors and uses thereof
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
MX2021014455A (es) Inhibidores de proteina cinasas dependientes de adn.
EA201691930A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-α][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1
WO2014125408A3 (en) Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
PH12017501699A1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
MX2023011065A (es) Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.
MX2019014845A (es) Compuestos de aminotiazol como inhibidores de la proteina quinasa.
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
MX2023011829A (es) Derivados de uracilo como inhibidores de trpa1.
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
PH12017501334B1 (en) 3,5-diaminopyrazole kinase inhibitors
EA201990046A1 (ru) Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета